IL240594A0 - Bispecific and sequential fc antibodies against met-c - Google Patents

Bispecific and sequential fc antibodies against met-c

Info

Publication number
IL240594A0
IL240594A0 IL240594A IL24059415A IL240594A0 IL 240594 A0 IL240594 A0 IL 240594A0 IL 240594 A IL240594 A IL 240594A IL 24059415 A IL24059415 A IL 24059415A IL 240594 A0 IL240594 A0 IL 240594A0
Authority
IL
Israel
Prior art keywords
tandem
met
bispecific antibodies
bispecific
antibodies
Prior art date
Application number
IL240594A
Other languages
English (en)
Hebrew (he)
Original Assignee
Merrimack Pharmaceuticals Inc
Adimab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc, Adimab Llc filed Critical Merrimack Pharmaceuticals Inc
Publication of IL240594A0 publication Critical patent/IL240594A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
IL240594A 2013-03-06 2015-08-16 Bispecific and sequential fc antibodies against met-c IL240594A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361773788P 2013-03-06 2013-03-06
US201361773764P 2013-03-06 2013-03-06
PCT/US2014/021341 WO2014138449A1 (en) 2013-03-06 2014-03-06 Anti-c-met tandem fc bispecific antibodies

Publications (1)

Publication Number Publication Date
IL240594A0 true IL240594A0 (en) 2015-09-24

Family

ID=50483485

Family Applications (1)

Application Number Title Priority Date Filing Date
IL240594A IL240594A0 (en) 2013-03-06 2015-08-16 Bispecific and sequential fc antibodies against met-c

Country Status (15)

Country Link
US (2) US9458245B2 (https=)
EP (1) EP2964676A1 (https=)
JP (1) JP2016510755A (https=)
KR (1) KR20150143458A (https=)
CN (1) CN105705519A (https=)
AU (1) AU2014225661A1 (https=)
BR (1) BR112015021462A2 (https=)
CA (1) CA2902505A1 (https=)
EA (1) EA201591652A1 (https=)
HK (1) HK1220465A1 (https=)
IL (1) IL240594A0 (https=)
MX (1) MX2015011712A (https=)
SG (1) SG11201506451UA (https=)
TW (1) TW201444872A (https=)
WO (1) WO2014138449A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US9605084B2 (en) * 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
HK1220465A1 (zh) * 2013-03-06 2017-05-05 Merrimack Pharmaceuticals, Inc. 抗c-met串联fc双特异性抗体
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP3613433B1 (en) 2014-05-30 2022-01-05 Shanghai Henlius Biotech, Inc. Anti-epidermal growth factor receptor (egfr) antibodies
US20170306415A1 (en) * 2014-10-01 2017-10-26 Merrimack Phamaceuticals, Inc. Predicting tumor responses to antibodies against hepatocyte growth factor (hgf) and/or its cognate receptor, c-met
KR101631646B1 (ko) * 2014-10-16 2016-06-20 주식회사 파멥신 VEGFR-2 및 c-Met에 대하여 결합성을 갖는 이중표적항체
JP6668345B2 (ja) * 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
PE20171324A1 (es) 2014-11-26 2017-09-11 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
WO2017070356A1 (en) * 2015-10-23 2017-04-27 Merrimack Pharmaceuticals, Inc. DOSAGE AND ADMINISTRATION OF ANTI-c-MET, ANTI-EpCAM BISPECIFIC ANTIBODIES, USES THEREOF AND MENTHODS OF TREATMENT THEREWITH
HRP20220064T1 (hr) * 2015-10-30 2022-04-15 F. Hoffmann - La Roche Ag Zglobno modificirani fragmenti protutijela i postupci za pripravu
IL313507A (en) * 2016-02-03 2024-08-01 Amgen Res Munich Gmbh Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
EA201891753A1 (ru) * 2016-02-03 2019-01-31 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
CN106397598B (zh) * 2016-02-23 2020-07-14 上海交通大学 多价多特异性抗体及免疫杂合蛋白的表达和制备方法
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
WO2018129397A1 (en) * 2017-01-06 2018-07-12 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
EP3743445A1 (en) * 2018-01-26 2020-12-02 City of Hope Chimeric antigen receptors and methods for reducing off target toxicity
AR115730A1 (es) 2018-07-10 2021-02-17 Regeneron Pharma Modificación de moléculas de unión para minimizar interacciones pre-existentes
US20210238310A1 (en) * 2018-07-11 2021-08-05 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
EA202190986A1 (ru) 2018-11-26 2021-12-14 Фоти Севен, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit
JP2022510218A (ja) * 2018-11-30 2022-01-26 メモリアル スローン ケタリング キャンサー センター ヘテロ二量体四価特異性抗体およびこれらの使用
WO2020160189A1 (en) * 2019-01-29 2020-08-06 Gritstone Oncology, Inc. Multispecific binding proteins
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging
CN120383671A (zh) * 2019-09-30 2025-07-29 阿迪马布有限责任公司 被工程化用于优先轻链配对的ch1结构域变体和包括所述ch1结构域变体的多特异性抗体
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
US20230265176A1 (en) * 2020-08-14 2023-08-24 Chugai Seiyaku Kabushiki Kaisha One-armed antigen-binding molecules and uses thereof
CA3207821A1 (en) * 2020-12-10 2022-06-16 Invenra Inc. Orthogonal mutations for heterodimerization
CN112979827A (zh) * 2021-03-04 2021-06-18 华东理工大学 一种抗EGFR scFv::FTH1/FTH1蛋白纳米粒子的应用
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
CN113234165B (zh) * 2021-05-07 2023-02-28 暨南大学 EpCAM的改造的结合蛋白及其应用
CN118354789A (zh) * 2021-09-03 2024-07-16 Go医疗股份有限公司 抗糖-cMET抗体及其用途
CN116554340A (zh) * 2022-01-28 2023-08-08 江苏众红生物工程创药研究院有限公司 新型长效化和高活性且更安全的抗体构建体
EP4724490A2 (en) 2023-06-12 2026-04-15 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins
CN120271706A (zh) * 2023-12-29 2025-07-08 上海安领科生物医药有限公司 抗egfr单抗、其双特异性抗体、药物组合物和用途

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5468468A (en) 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
DE4205148A1 (de) 1991-05-25 1993-01-21 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen c-kit
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6696548B2 (en) 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20020136721A1 (en) * 1998-02-17 2002-09-26 Schwall Ralph H. Hepatocyte growth factor receptor antagonists and uses thereof
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
AU5286999A (en) 1999-07-23 2001-02-13 Glaxo Group Limited Combination of an anti-ep-cam antibody with a chemotherapeutic agent
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
JP4132547B2 (ja) 2000-03-01 2008-08-13 富士フイルム株式会社 画像形成材料及びそれを用いた平版印刷版原版
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
ME00502B (me) 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
AU2002307037B2 (en) 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
EP1383785B1 (en) 2001-05-03 2011-03-16 Merck Patent GmbH Recombinant tumor specific antibody and use thereof
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
EP1406931A2 (en) 2001-07-19 2004-04-14 Universität Zürich Modification of human variable domains
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
EP1469878B1 (en) 2002-01-31 2011-03-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Fgfr agonists
EP2298346A3 (en) 2002-03-04 2011-11-16 Imclone LLC Human antibodies specific to kdr and uses thereof
JP4585968B2 (ja) 2002-05-10 2010-11-24 パーデュー・リサーチ・ファウンデーション ＥｐｈＡ２アゴニストモノクローナル抗体およびその使用法
US20080008713A1 (en) 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
BRPI0407446A (pt) 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
ITMI20031127A1 (it) 2003-06-05 2004-12-06 Uni Degli Studi Del Piemont E Orientale Am Anticorpi anti-hgf-r e loro uso
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
EP2060270A3 (en) 2003-10-16 2009-12-09 Imclone LLC Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
DK1771482T3 (da) 2004-07-22 2014-10-20 Genentech Inc HER2-antistofsammensætning
CA2575402A1 (en) 2004-08-05 2006-02-09 Genentech, Inc. Humanized anti-cmet antagonists
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
CN101155830B (zh) 2005-02-04 2014-06-18 雷文生物技术公司 结合epha2的抗体及其使用方法
PL1871805T3 (pl) 2005-02-07 2020-03-31 Roche Glycart Ag Cząsteczki wiążące antygen, które wiążą egfr, wektory kodujące te cząsteczki oraz ich zastosowania
NZ561211A (en) 2005-03-25 2011-03-31 Genentech Inc Methods and compositions for modulating hyperstabilized C-met
BRPI0611445A2 (pt) 2005-05-09 2010-09-08 Glycart Biotechnology Ag molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica
CA2612449A1 (en) 2005-06-17 2006-12-28 Imclone Systems Incorporated Receptor antagonists for treatment of metastatic bone cancer
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
AU2007213920B2 (en) 2006-02-09 2013-08-29 Amgen Research (Munich) Gmbh Treatment of metastatic breast cancer
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
US8101727B2 (en) 2006-03-30 2012-01-24 Novartis Ag Compositions and methods of use for antibodies of c-Met
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
BRPI0710971A2 (pt) 2006-04-28 2011-05-31 Esbatech Ag anticorpos que se ligam ao domìnio extracelular do receptor tirosina cinase alk,seu uso, vetor de expressão,método para produção de um antcorpo, vacina e epìtodo de alk
EP2094733A1 (en) 2006-11-03 2009-09-02 U3 Pharma GmbH Fgfr4 antibodies
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
ES2368764T3 (es) 2007-03-19 2011-11-22 Universität Stuttgart ANTAGONISTAS SELECTIVOS DE huTNFR1.
CA2682390A1 (en) 2007-04-17 2008-10-30 Imclone Llc Pdgfr.beta.-specific inhibitors
EP2144930A1 (en) * 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
WO2008131575A2 (en) 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
CA2700815A1 (en) 2007-09-27 2009-04-02 Viventia Biotech Inc. Optimized nucleic acid sequences for the expression of vb4-845
JP5769969B2 (ja) 2007-11-12 2015-08-26 ユー３・ファーマ・ゲーエムベーハー Ａｘｌ抗体
CL2008003449A1 (es) 2007-11-21 2010-02-19 Imclone Llc Anticuerpo o fragmentos del mismo contra el receptor de proteína estimulante de macrófagos/ron; composición farmacéutica que lo comprende; uso para inhibir angiogénesis, crecimiento tumoral, proliferación, migración e invasión de células tumorales, activación de ron o fosforilación de mapk y/o akt; y uso para tratar cáncer.
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
JP2011509687A (ja) 2008-01-22 2011-03-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｒｏｎ抗体およびその使用
MX2010011145A (es) * 2008-04-11 2011-04-11 Merrimack Pharmaceuticals Inc Enlazadores de la albumina de suero humana y conjugados de la misma.
US20100009390A1 (en) 2008-05-09 2010-01-14 The Regents Of The University Of California Mutant antibodies with high affinity for egfr
EP2313435A4 (en) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
WO2010064090A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Process for the modulation of the antagonistic activity of a monoclonal antibody
EP2417164A1 (en) 2009-04-07 2012-02-15 Roche Glycart AG Bispecific anti-erbb-2/anti-c-met antibodies
KR20120024763A (ko) 2009-05-15 2012-03-14 추가이 세이야쿠 가부시키가이샤 항ａｘｌ 항체
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
WO2011028952A1 (en) * 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2496601B1 (en) 2009-11-05 2017-06-07 F. Hoffmann-La Roche AG Methods and composition for secretion of heterologous polypeptides
PT3904391T (pt) * 2010-03-10 2024-10-14 Genmab As Anticorpos monoclonais contra c-met
MX343227B (es) 2010-04-09 2016-10-28 Aveo Pharmaceuticals Inc Anticuerpos anti-erbb3.
RU2012153241A (ru) 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. Антитела к fgfr2
RU2577986C2 (ru) 2010-06-18 2016-03-20 Дженентек, Инк. Антитела против axl и способы их применения
AR082194A1 (es) 2010-07-06 2012-11-21 Aveo Pharmaceuticals Inc Anticuerpos anti-ron
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
HK1220465A1 (zh) * 2013-03-06 2017-05-05 Merrimack Pharmaceuticals, Inc. 抗c-met串联fc双特异性抗体

Also Published As

Publication number Publication date
BR112015021462A2 (pt) 2017-10-10
CA2902505A1 (en) 2014-09-12
CN105705519A (zh) 2016-06-22
AU2014225661A1 (en) 2015-09-10
US9458245B2 (en) 2016-10-04
WO2014138449A1 (en) 2014-09-12
TW201444872A (zh) 2014-12-01
JP2016510755A (ja) 2016-04-11
US20140302035A1 (en) 2014-10-09
MX2015011712A (es) 2016-04-04
KR20150143458A (ko) 2015-12-23
SG11201506451UA (en) 2015-09-29
HK1220465A1 (zh) 2017-05-05
US20170081421A1 (en) 2017-03-23
EP2964676A1 (en) 2016-01-13
EA201591652A1 (ru) 2016-02-29

Similar Documents

Publication Publication Date Title
IL240594A0 (en) Bispecific and sequential fc antibodies against met-c
ZA201808451B (en) Anti-fcrh5 antibodies
ZA201506568B (en) Anti-tnf-anti-il-17 bispecific antibodies
PL3049439T3 (pl) Bispecyficzne nanociała
IL230772A0 (en) Specific antibodies with subsequent fc
GB201311487D0 (en) Bispecific molecules
GB201322583D0 (en) Antibodies
EP3083698A4 (en) Monoclonal anti-tk1 antibodies
SG11201506647SA (en) Bispecific bivalent scfv-fc molecules
ZA201407272B (en) Anti-baff-anti-il-17 bispecific antibodies
ZA201601437B (en) Antibodies
GB201308658D0 (en) Antibodies
GB201315486D0 (en) Antibodies
EP3143154A4 (en) Chemically-locked bispecific antibodies
EP2970445A4 (en) Humanized anti-n2 antibodies
IL245488B (en) Anti- ccl17 antibodies
GB201312226D0 (en) Improved antibodies
GB201318283D0 (en) Antibodies
HK1235274A1 (en) Anti-il-4-il-13 bispecific antibodies
AU2013904054A0 (en) Tandem